#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2216	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2512	177.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1939	1939	T	257	T	158	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2216	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2512	177.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1673	1673	C	276	C	174	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3856	208.8	0	.	n	.	0	T695C	SNP	695	695	T	1212	1212	C	316	C	201	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3856	208.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1854	1854	A	252	A	168	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3856	208.8	0	.	n	.	0	A1638G	SNP	1638	1638	A	2155	2155	G	217	G	148	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3856	208.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2488	2488	C	194	C	116	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3856	208.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2562	2562	A	215	A	136	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3856	208.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3114	3114	C	272	C	176	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3856	208.8	0	HET	.	.	.	C2525T	.	2525	2525	C	3042	3042	C	251	C,T	127,42	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	126	folP	855	855	100.0	folP.l15.c4.ctg.1	1195	19.4	1	SNP	p	R229S	1	.	.	685	687	AGC	791	793	AGC	18;18;18	A;G;C	11;12;11	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	366	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3263	21.7	1	SNP	p	S91F	1	.	.	271	273	TTC	390	392	TTC	32;32;32	T;T;C	20;21;21	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	366	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3263	21.7	1	SNP	p	G95N	0	.	.	283	285	GGC	402	404	GGC	31;32;32	G;G;C	22;22;21	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	366	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3263	21.7	1	SNP	p	D95G	1	.	.	283	285	GGC	402	404	GGC	31;32;32	G;G;C	22;22;21	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	134	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1678	16.7	1	SNP	p	G45D	0	.	.	133	135	GGC	419	421	GGC	44;44;44	G;G;C	30;30;27	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	114	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	501	39.1	0	.	n	.	0	A197.	DEL	197	197	A	280	280	A	62	A	36	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	324	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2901	20.5	1	SNP	p	D86N	0	.	.	256	258	GAC	578	580	GAC	22;22;22	G;A;C	15;14;15	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	324	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2901	20.5	1	SNP	p	R87I	0	.	.	259	261	CGT	581	583	CGT	22;22;23	C;G;T	15;15;15	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	324	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2901	20.5	1	SNP	p	R87W	0	.	.	259	261	CGT	581	583	CGT	22;22;23	C;G;T	15;15;15	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	324	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2901	20.5	1	SNP	p	S87R	1	.	.	259	261	CGT	581	583	CGT	22;22;23	C;G;T	15;15;15	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	324	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2901	20.5	1	SNP	p	S88P	0	.	.	262	264	TCC	584	586	TCC	24;24;24	T;C;C	15;15;15	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	296	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2636	22.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1588	1590	GGC	21;21;21	G;G;C	16;16;16	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1097	1099	GCA	44;45;45	G;C;A	30;25;29	penA.41.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1100	1102	ATC	45;46;46	A;T;C	28;30;27	penA.41.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1112	1114	GTG	45;45;45	G;T;G	31;28;27	penA.41.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1112	1114	GTG	45;45;45	G;T;G	31;28;27	penA.41.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1616	1618	ACC	25;25;25	A;C;C	14;16;16	penA.41.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1670	1672	GCG	25;25;25	G;C;G	17;15;14	penA.41.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1670	1672	GCG	25;25;25	G;C;G	17;15;14	penA.41.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1793	1795	AGC	28;29;29	A;G;C	17;17;20	penA.41.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1802	1804	GGC	24;24;23	G;G;C	16;16;14	penA.41.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.41.001	penA.41.001	1	1	27	402	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2104	36.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1820	1822	CCG	23;23;23	C;C;G	11;13;11	penA.41.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	678	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3013	41.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1728	1730	CCG	20;20;20	C;C;G	13;15;14	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	186	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1833	18.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	603	603	C	10	C	5	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	414	416	GAA	56;56;56	G;A;A	39;39;39	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	1	SNP	p	D121N	1	D121N	NONSYN	361	363	GAC	663	665	AAC	36;36;36	A;A;C	24;27;26	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	702	704	GAT	46;47;47	G;A;T	31;30;33	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	825	827	TCA	48;46;46	T;C;A	32;31;30	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	0	.	p	.	0	A218I	NONSYN	652	654	GCC	954	956	ATC	54;59;59	A;T;C	34;38;36	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	0	.	p	.	0	R258H	NONSYN	772	774	CGT	1074	1076	CAT	49;46;44	C;A;T	31;30;28	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	0	.	p	.	0	S295G	NONSYN	883	885	AGT	1185	1187	GGT	38;38;38	G;G;T	28;28;27	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1284	1286	GCA	34;34;31	G;C;A	24;24;21	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	296	porB1b	1047	1047	98.95	porB1b.l6.c4.ctg.1	1746	33.6	1	SNP	p	G120K	1	.	.	358	360	AAG	660	662	AAG	35;35;35	A;A;G	27;28;27	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1160	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4836	45.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	112	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	932	23.6	1	SNP	p	V57M	1	.	.	169	171	ATG	498	500	ATG	35;35;35	A,T;T;G	23,1;24;22	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
